Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2016

Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2016
Published Jul 13, 2016
71 pages — Published Jul 13, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2016, provides an overview of the Venous Leg Ulcers (Crural ulcer) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Venous Leg Ulcers (Crural ulcer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Venous Leg Ulcers (Crural ulcer) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Venous Leg Ulcers (Crural ulcer)
- The report reviews pipeline therapeutics for Venous Leg Ulcers (Crural ulcer) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Venous Leg Ulcers (Crural ulcer) therapeutics and enlists all their major and minor projects
- The report assesses Venous Leg Ulcers (Crural ulcer) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Venous Leg Ulcers (Crural ulcer)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Venous Leg Ulcers (Crural ulcer)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline

  
Source:
Document ID
GMDHC8235IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Venous Leg Ulcers (Crural ulcer) Overview71
Therapeutics Development81
  Pipeline Products for Venous Leg Ulcers (Crural ulcer) Overview81
Venous Leg Ulcers (Crural ulcer) Therapeutics under Development by Companies91
Venous Leg Ulcers (Crural ulcer) Pipeline Products Glance104
  Late Stage Products101
  Clinical Stage Products111
  Early Stage Products121
  Unknown Stage Products131
Venous Leg Ulcers (Crural ulcer) Products under Development by Companies141
Venous Leg Ulcers (Crural ulcer) Companies Involved in Therapeutics Development1511
  Adocia151
  CardioVascular BioTherapeutics, Inc.161
  CytoTools AG171
  FirstString Research, Inc.181
  MacroCure Ltd.191
  MediWound Ltd.201
  NovaLead Pharma Pvt. Ltd.211
  Pergamum AB221
  RegeneRx Biopharmaceuticals, Inc.231
  Stratatech Corporation241
  Tissue Therapies Limited251
Venous Leg Ulcers (Crural ulcer) Therapeutics Assessment269
  Assessment by Monotherapy Products261
  Assessment by Target272
  Assessment by Mechanism of Action292
  Assessment by Route of Administration312
  Assessment by Molecule Type332
Drug Profiles3525
  Biochaperone PDGF-BB Drug Profile352
  Cell Therapy to Activate Cathelicidin for Diabetic Foot Ulcers and Crural Ulcer Drug Profile372
  Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers Drug Profile391
  CL-05 Drug Profile403
  CODA-001 Drug Profile432
  CureXcell Drug Profile451
  CVBT-141B Drug Profile462
  EscharEx Drug Profile482
  Granexin Drug Profile502
  LL-37 Drug Profile522
  NLP-328 Drug Profile541
  PAC-G Drug Profile551
  RGN-137 Drug Profile562
  Stathmin-1 Drug Profile581
  VF-001 Drug Profile591
Venous Leg Ulcers (Crural ulcer) Dormant Projects601
Venous Leg Ulcers (Crural ulcer) Discontinued Products611
Venous Leg Ulcers (Crural ulcer) Product Development Milestones628
  Featured News &Press Releases621
    May 23, 2016: CytoTools confirms the clinical efficacy of DermaPro in phase II/III trial621
    Dec 17, 2015: Tissue Therapies Provides FDA Regulatory Progress Update621
    Aug 19, 2015: Macrocure Provides Update on Futility Analysis for Phase III Clinical Trial of CureXcell in Venous Leg Ulcers631
    Jul 22, 2015: RegeneRx Receives Notice of Acceptance for Australian Patent for Key TB4 Peptide Fragment641
    Apr 21, 2015: SCRA Technology Ventures Company Shares Phase 2 Results641
    Apr 15, 2015: CytoTools: Recruitment Of Patients Now Complete For European Studies On Diabetic Foot And Ulcus Cruris Indications651
    May 05, 2014: Subsidiary DermaTools Biotech starts European clinical phase II/III trial with wound healing medication DermaPro for ulcus cruris indication661
    Oct 10, 2013: Pergamum announces final data from Phase I/II study of LL-37 in patients with chronic leg ulcers661
    Apr 19, 2013: Pergamum Reaches Last-Patient-Last-Visit In Phase I/II Trial Of LL-37 For Treatment Of Venous Leg Ulcers671
    Jan 09, 2013: CoDa Therapeutics Announces Positive Results From Phase IIb Study Of Nexagon In Chronic Venous Leg Ulcers681
    Sep 11, 2012: Pergamum Announces Dosing Of First Patient In Phase I/II trial Of LL-37 For Hard-to-heal Wounds681
    Mar 26, 2009: RegeneRx Reports Phase II Venous Stasis Trial Results681
    Feb 26, 2009: RegeneRx Updates On Phase II Venous Stasis Trial691
Appendix702
  Methodology701
  Coverage701
  Secondary Research701
  Primary Research701
  Expert Panel Validation701
  Contact Us701
  Disclaimer711

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2016" Jul 13, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Venous-Leg-Ulcers-Crural-ulcer-Pipeline-Review-H2-2016-2088-16168>
  
APA:
Global Markets Direct - Market Research. (2016). Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2016 Jul 13, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Venous-Leg-Ulcers-Crural-ulcer-Pipeline-Review-H2-2016-2088-16168>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.